Please login to the form below

Not currently logged in
Email:
Password:

CROS NT appoints Andrew MacGarvey to lead new UK office

Contract research organisation's new facility will be based in Milton Keynes

CROS NT Andrew MacGarveyItalian contract research organisation CROS NT has expanded into the UK and appointed Andrew MacGarvey to lead operations from its new facility in Milton Keynes.

MacGarvey has over 15 years' experience within the pharmaceutical sector and as CROS NT's new vice president of UK and USA operations he will be tasked with growing ties with the contract research organisation's UK-based customers.

MacGarvey previously held senior management and director roles at multiple contract research organisation (CROs) in Europe and the US.

"I have followed the activities of CROS NT for some time," MacGarvey said. "I am excited by the opportunity to help with the growth of the business. CROS NT are focused on customer care, something that is very important to me. I will be bringing their great service to the UK and ultimately the US."

Verona-headquartered CROS NT's new UK base joins its existing facilities in Italy and Augsburg, Germany.

17th August 2012

Share

Related Hub content

    Your search did not contain any words. Please try again.

Featured jobs

Senior Brand Manager - Harlow
Competitive
Sales Manager - Media Publishing – Cheshire
25,000 to 35,000 per annum
UK Marketing Director
80,000 to 100,000 per annum
Group Account Director –Healthcare Advertising
Neg

Subscribe to our email news alerts

PMHub

Add my company
nitrogen

At nitrogen being creative is part of everyone’s role, whether they’re a science writer, account handler or digital ...

Latest intelligence

Clinical trial regulation in Mexico
Regulatory improvements make Mexico an appealing destination for clinical trials outsourcing...
Online Physician Communities
How can pharma deliver returns on increased digital investment?
Independent online professional networks work best as part of a multi-channel campaign  ...
The impact of Hollande's healthcare reforms in France
A tougher environment for pharma, with market access and regulatory challenges...